Arbutus Biopharma
$4.5
66
-$0-0.11% Today
Statistics
Day High
4.62
Day Low
4.47
52W High
5.1
52W Low
2.71
Volume
549,298
Avg. Volume
2,237,934
Mkt Cap
862.83M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
30AprExpected
Expected EPS
-0.04
Actual EPS
N/A
Financials
-1,133.04%Profit Margin
Unprofitable12.34MRevenue
-139.84MNet Income
Analyst Ratings
$5.00Average Price Target
The highest estimate is 5.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ABUS. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Arrowhead Pharmaceuticals
ARWR
Mkt Cap5.86B
Gilead Sciences
GILD
Mkt Cap148.78B
Abbott Laboratories
ABT
Mkt Cap214.96B
Johnson & Johnson
JNJ
Mkt Cap455.04B
Pfizer
PFE
Mkt Cap140.15B
BioNTech
BNTX
Mkt Cap24.99B
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
About
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Show more...
CEO
Ms. Lindsay Androski J.D., M.B.A.
Employees
44
Country
CA
ISIN
CA03879J1003
Listings
0 Comments
Share your thoughts
FAQ
What is Arbutus Biopharma stock price today?▼
The current price of ABUS is $4.5 USD — it has decreased by -0.11% in the past 24 hours. Watch Arbutus Biopharma stock price performance more closely on the chart.
What is Arbutus Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Arbutus Biopharma stocks are traded under the ticker ABUS.
Is Arbutus Biopharma stock price growing?▼
ABUS stock has fallen by -0.55% compared to the previous week, the month change is a -3.33% fall, over the last year Arbutus Biopharma has showed a +29.45% increase.
What is Arbutus Biopharma market cap?▼
Today Arbutus Biopharma has the market capitalization of 862.83M
When is the next Arbutus Biopharma earnings date?▼
Arbutus Biopharma is going to release the next earnings report on April 30, 2026.
What were Arbutus Biopharma earnings last quarter?▼
ABUS earnings for the last quarter are -0.04 USD per share, whereas the estimation was -0.03 USD resulting in a -33.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Arbutus Biopharma revenue for the last year?▼
Arbutus Biopharma revenue for the last year amounts to 12.34M USD.
What is Arbutus Biopharma net income for the last year?▼
ABUS net income for the last year is -139.84M USD.
How many employees does Arbutus Biopharma have?▼
As of April 01, 2026, the company has 44 employees.
In which sector is Arbutus Biopharma located?▼
Arbutus Biopharma operates in the Health Care sector.
When did Arbutus Biopharma complete a stock split?▼
Arbutus Biopharma has not had any recent stock splits.
Where is Arbutus Biopharma headquartered?▼
Arbutus Biopharma is headquartered in Warminster, CA.